Releases
CTMX
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Cytomx Therapeutics Inc (CTMX) stock and general news. This information may help you make smarter investment decisions.
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The Company's product candidates include the conditionally activated antibody-drug conjugates (ADCs) praluzatamab ravtansine (CX2009, targeting CD166) and CX-2029, targeting CD71, and the Probody immune checkpoint inhibitors pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4). It also has two preclinical agents in investigational new drug (IND)-enabling studies - a conditionally activated ADC targeting EpCAM/Trop-1 (CX-2043) and a conditionally activated T-cell engaging bispecific antibody targeting EGFR and CD3 (CX-904).